I'm out as well, 25 units was really underwhelming to say the least, doesn't even cover the costs of sales staff, I'm certain central blood pressure measurement will become the norm in the future but looks like they aren't getting any traction at the prices atcor are charging.
Maybe pricing is the issue as competition should be arriving soon priced at $USD 3k so if they were priced at $USD 5k they might still sell due to being a premium product with more trial data but otherwise clinicians are happy to wait another since no one else is really using central blood pressure measurements currently anyway.
Ann: FY2016 results-ACG.AX, page-17
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.82M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60000 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 44999 | 1 |
View Market Depth
| Last trade - 16.12pm 23/07/2024 (20 minute delay) ? |
| CDX (ASX) Chart |
Day chart unavailable